Organism: Homo sapiens
Gene: 1552398_a_at
Selected probe(set): 1552398_a_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552398_a_at (1552398_a_at) across 6540 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):4.8143454
Number of Samples:75 / 441

Experimental	CML study 1
	Bone marrow samples of patients with chronic myeloid leukemia (CML).
Control	B-CLL study 5
	Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).

Relative Expression (log2-ratio):-4.6178093
Number of Samples:40 / 74

Experimental	B-ALL study 1 (hyperdiploid)
	Bone marrow samples of patients with hyperdiploid B-ALL (hyperdiploid karyotype).
Control	normal bone marrow sample
	Non-leukemic and healthy bone marrow sample.

Relative Expression (log2-ratio):-4.4812717
Number of Samples:58 / 74

Experimental	precursor-B-ALL study 1 (t(12;21)(p12,q22))
	Bone marrow samples of patients with precursor B-ALL (t(12;21)(p12,q22)/TEL-AML1).
Control	normal bone marrow sample
	Non-leukemic and healthy bone marrow sample.

Relative Expression (log2-ratio):-4.352275
Number of Samples:36 / 74

Experimental	precursor-B-ALL study 1 (t(1;19)(q23,q13))
	Bone marrow samples of patients with precursor B-ALL (t(1;19)(q23,q13)/E2A-PBX1).
Control	normal bone marrow sample
	Non-leukemic and healthy bone marrow sample.

Relative Expression (log2-ratio):-4.3069525
Number of Samples:70 / 74

Experimental	precursor-B-ALL study 1 (t(11q23))
	Bone marrow samples of patients with precursor B-ALL (t(11q23)/MLL).
Control	normal bone marrow sample
	Non-leukemic and healthy bone marrow sample.

Relative Expression (log2-ratio):-4.074356
Number of Samples:441 / 74

Experimental	B-CLL study 5
	Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).
Control	normal bone marrow sample
	Non-leukemic and healthy bone marrow sample.

Relative Expression (log2-ratio):-3.9970865
Number of Samples:7 / 3

Experimental	Langerhans cell histiocytosis study 1
	Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity.
Control	normal myeloid dendritic cell sample
	Normal myeloid dendritic cells were isolated from peripheral blood of healthy adult donors. Myeloid dendritic cells were defined as HLA-DR+ / CD11c + / BDCA1+ / BDCA3- population.

Relative Expression (log2-ratio):3.985446
Number of Samples:3 / 2

Experimental	DLBCL study 7 (GCB; plasmablast-like)
	Primary tumor samples from patients with diffuse large B-cell lymphoma (germinal center B-cell like type). Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS) and assigned to plasmablast-like group. Patients were treated according to standard protocols, and comparable doses of RCHOP- like regimens were used. No patient was treated with stem cell transplantation.
Control	DLBCL study 7 (GCB; naive-like)
	Primary tumor samples from patients with diffuse large B-cell lymphoma (germinal center B-cell like type). Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS) and assigned to naive-like group. Patients were treated according to standard protocols, and comparable doses of RCHOP- like regimens were used. No patient was treated with stem cell transplantation.

Relative Expression (log2-ratio):3.8847342
Number of Samples:13 / 5

Experimental	cutaneous sarcoidosis study 1 (lesional)
	Lesional skin biopsies from patients with acute cutaneous sarcoidosis.
Control	normal skin tissue
	Skin biopsy samples from healthy control subjects.

Relative Expression (log2-ratio):-3.8592615
Number of Samples:121 / 74

Experimental	c-ALL/pre-B-ALL study 1 (t(9;22)(q34,q11))
	Bone marrow samples of patients with c-ALL/pre-B-ALL (t(9;22)(q34,q11)/BCR-ABL).
Control	normal bone marrow sample
	Non-leukemic and healthy bone marrow sample.